48,466
edits
(→Pancreas neoplasms in a table: +images) |
(→IPMT: update) |
||
Line 280: | Line 280: | ||
*Prognosis of m. cystadenocarcinoma is slightly better than that of ductal adenocarcinoma. | *Prognosis of m. cystadenocarcinoma is slightly better than that of ductal adenocarcinoma. | ||
== | ==Intraductal papillary mucinous tumour== | ||
Intraductal papillary mucinous tumour | ===General=== | ||
*Often abbreviated ''IPMT''. | |||
*Papillomatous growth pattern. | *Papillomatous growth pattern. | ||
*Morphologically and biologically distinct from ductal adenocarcinoma, mucinous cystic tumour and ductal papillary hyperplasia. | *Morphologically and biologically distinct from ductal adenocarcinoma, mucinous cystic tumour and ductal papillary hyperplasia. | ||
===Epidemiology=== | |||
*1% of all exocrine pancreatic tumours. | *1% of all exocrine pancreatic tumours. | ||
*More common in males. | *More common in males. | ||
*Mean age at presentation 62 years. | *Mean age at presentation 62 years. | ||
*60-80% occur in the head of the pancreas | *60-80% occur in the head of the pancreas. | ||
* | *Average size 4 cm. | ||
Khalifa's theory: | Khalifa's theory: | ||
*Nothing but dilation of pancreatic duct + hypersecretion. | *Nothing but dilation of pancreatic duct + hypersecretion. | ||
====Adenoma-carcinoma sequence==== | |||
3Hyperplasia. | |||
#Adenomatous hyperplasia. | |||
#Carcinoma in situ. | |||
#Invasive carcinoma. | |||
Note: K-ras oncogene mutation associated - seen in all stages of the sequence. | |||
===Gross=== | |||
*May be patchy/multifocal. | |||
===Microscopic=== | |||
Features | |||
*Cell enlargement. | *Cell enlargement. | ||
*Incr. NC ratio. | *Incr. NC ratio. | ||
Line 312: | Line 316: | ||
*Increased mucin production. | *Increased mucin production. | ||
=== | ===Classification IMPT=== | ||
*Adenoma. | *Adenoma. | ||
*Borderline mucinous tumour. | *Borderline mucinous tumour. | ||
*Carcinoma. | *Carcinoma. | ||
NB1 | NB1 |
edits